Clinical trial
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic…
NCT00053248 · OHSU Knight Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00053248 |
|---|---|
| Title | Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | A Phase I/II Study To Determine The Safety, Tolerability, And Anti-Leukemic Effects of Trisenox (Arsenic Trioxide) In Combination With Gleevec (STI571) In Patients With Resistant Chronic Myelogenous Leukemia In Chronic Phase |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | arsenic trioxide, imatinib mesylate |
| Enrollment | 16 |
| Start date | Oct 1, 2002 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Jan 28, 2003 |
| Last update posted | May 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: